GAITHERSBURG, Md., May 13, 2024
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company
advancing protein-based vaccines with its Matrix-M™ adjuvant, today
announced it will participate in the BofA Securities 2024 Health
Care Conference.
|
Conference
Details:
|
|
|
|
Fireside
Chat
|
|
|
Date:
|
Wednesday, May 15,
2024
|
|
Time:
|
3:00 – 3:30 p.m.
Pacific Daylight Time (PDT)
|
|
Location:
|
Encore Hotel in Las
Vegas, NV
|
|
Moderator:
|
Alec Stranahan, PhD,
Equity Research – U.S. Biopharma
|
|
Novavax
participant:
|
John C. Jacobs,
President and Chief Executive Officer
|
|
|
|
Conference
|
|
|
Event:
|
Investor
Meetings
|
|
Date:
|
Wednesday, May 15,
2024
|
Recordings
A replay of the recorded fireside session
will be available through the Events & Presentations page of
the Company's website at ir.novavax.com for 30 days from the date
of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a
differentiated vaccine platform that combines a recombinant protein
approach, innovative nanoparticle technology and Novavax's patented
Matrix-M adjuvant to enhance the immune response. The Company's
portfolio includes its COVID-19 vaccine and its pipeline includes
COVID-19-Influenza Combination and stand-alone influenza vaccine
candidates. In addition, Novavax's adjuvant is included in the
University of Oxford and Serum
Institute of India's R21/Matrix-M
malaria vaccine. Please visit novavax.com and
LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Giovanna Chandler
202-709-5563
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-bofa-securities-2024-health-care-conference-302143793.html
SOURCE Novavax, Inc.